跳至主要内容
临床试验/EUCTR2012-005375-14-ES
EUCTR2012-005375-14-ES进行中(未招募)1 期

A prospective randomized clinical trial on 90Yttrium trans-arterialradio-Embolization (Therasphere) vs. standard of care (sorafenib)for the treatment of advanced Hepatocellular carcinoma (Hcc)with Portal Vein Thrombosis (PVT) - YES-P

ordion (Canada) Inc.0 个研究点目标入组 328 人开始时间: 2013年6月10日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
328

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - Patients over 18 years of age, regardless of race or gender
  • - Advanced stage HCC with PVT and no extrahepatic metastases
  • - Child-Pugh A
  • - ECOG 0-1
  • - No contraindication to study treatment or procedures
  • - Not eligible for curative treatment including liver transplant
  • - No prior external beam radiation therapy
  • - No previous treatment with Sorafenib for more than 4 weeks during the 2 previous months; no prior sorafenib-related toxicity
  • - No previous conventional or drug eluting TACE unless it was performed at least 6 months prior to screening phase
  • - No history of organ allograft
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 164
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 164

排除标准

  • Not applicable

研究者

发起方
ordion (Canada) Inc.

相似试验

进行中(未招募)
1 期
A prospective randomized clinical trial with the medical device Therasphere versus the drug sorafenib for the treatment of liver cancer (HCC) with a clot in the major liver (Portal Vein Thrombosis - PVT)Advanced Hepatocellular Carcinoma (HCC) with Portal Vein Thrombosis (PVT)MedDRA version: 17.0Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableSystem Organ Class: 100000004864MedDRA version: 17.0Level: PTClassification code 10036206Term: Portal vein thrombosisSystem Organ Class: 10019805 - Hepatobiliary disorders
EUCTR2012-005375-14-BEBiocompatibles UK Ltd318
进行中(未招募)
1 期
A prospective randomized clinical trial with the medical device Therasphere versus the drug sorafenib for the treatment of liver cancer (HCC) with a clot in the major liver (Portal Vein Thrombosis - PVT)Advanced Hepatocellular Carcinoma (HCC) with Portal Vein Thrombosis (PVT)MedDRA version: 18.0Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableSystem Organ Class: 100000004864MedDRA version: 18.0Level: PTClassification code 10036206Term: Portal vein thrombosisSystem Organ Class: 10019805 - Hepatobiliary disorders
EUCTR2012-005375-14-GBBiocompatibles UK Ltd318
已完成
2 期
Comparing hormone profile and outcomes of ovulation triggering with GnRH and HGC in IVFFemale infertility.Female infertility
IRCT2015060222541N1Vice Chancellor of Research, Shiraz University of Medical Sciences232
尚未招募
1 期
A prospective randomized controlled trial for Yan's Jiangzhi Decoction Combined with atorvastatin in the treatment of dyslipidemia complicated with carotid atherosclerosisdyslipidemiacarotid atherosclerosis
ITMCTR2000003687Shanghai Tenth People's Hospital
招募中
2 期
dsyapereunia female sexual dysfunctio
CTRI/2017/12/010947drnamratabbhagaje